Posted on

CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring

Loading

AlloSure Lung Represents First dd-cfDNA Approved by Medicare for Lung Transplant Patients

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx’s AlloSure® Lung donor-derived cell-free DNA (dd-cfDNA) molecular testing service has received Medicare coverage.

The MolDX technology assessment program has determined that AlloSure Lung will be covered under the existing Medicare Local Coverage Determination for Molecular Testing for Solid Organ Allograft Rejection for use in the surveillance setting in lung transplant patients, effective May 9, 2023.1 Read the complete press release on CareDx.com.

Loading
Posted on

CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress

Loading

Record Number of 65 Abstracts Showcasing CareDx Innovation Including Data Showing Clinical Utility of AlloSure Kidney to Guide Immunosuppression Management

Experts Review Advancements in Artificial Intelligence and Molecular Diagnostics During CareDx Symposium

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 American Transplant Congress (ATC) with 65 scientific presentations. CareDx will also be hosting a satellite symposium1 andsponsoring the Women’s Networking Event. The ATC meeting takes place June 3-7 in San Diego, California.

“We are proud to showcase our leadership with our highest-ever number of abstracts at the 2023 Transplant Congress with data that not only validates the performance of AlloSure® and AlloMap® but also demonstrates their clinical utility in the surveillance and management of patients,” said Reg Seeto, CEO and President of CareDx. “We’re also excited to have assembled a world-class panel of experts to describe the latest innovations in transplantation including the additive clinical value of incorporating our molecular biomarkers into artificial intelligence tools to drive earlier insights regarding a patient’s risk of rejection for more personalized, preventative care.”
Read the complete press release on CareDx.com.

Loading
Posted on

CareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum

Loading

CareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase its digital health portfolio and host a symposium which addresses barriers in access to transplantation at the 31st Annual UNOS Transplant Management Forum (TMF) taking place May 16-18 in Denver, Colorado. CareDx is the leading Diamond level sponsor of this year’s UNOS TMF.

“Improving the transplant journey is at the heart of everything we do, and we are thrilled to showcase how our investment in cutting-edge digital health solutions is making a meaningful impact across the board with ever-increasing adoption,” said Kashif Rathore, Chief of Patient and Digital Solutions at CareDx. “CareDx is proud to participate in this important yearly forum to demonstrate how our connected set of transplant management solutions enables more cohesive care in the complex transplant ecosystem.” Read the complete press release on CareDx.com.

Loading
Posted on

CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference

Loading

April 25, 2023

Posters and Symposium Highlight Utility of AlloSeq for HLA Typing, Organ Transplant Monitoring and Hematopoietic Stem Cell Monitoring

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase the latest developments across its AlloSeq®* portfolioduring the 36th European Immunogenetics and Histocompatibility Conference taking place April 26-29 in Nantes, France.
Read the complete press release on CareDx.com.

Loading
Posted on

CareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation

Loading

APRIL, 19, 2023

Data Highlights the Value of HeartCare and AlloSure Lung in Clinical Practice

Leading Experts Present Latest Advancements in Heart and Lung Transplantation During CareDx Symposia

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 43rd annual meeting & scientific sessions of the International Society for Heart and Lung Transplantation (ISHLT) with over 55 oral presentations and posters, and two symposia covering the latest advancements in surveillance and the clinical utility of these advancements in real-world applications for both heart and lung transplantation. The event will be held April 19-22 in Denver, Colorado. Read the complete press release on CareDx.com.

Loading
Posted on

National Kidney Foundation Honors CareDx with Corporate Citizenship Award for its Commitment to the Transplant Community

Loading

April 6, 2023

National Kidney Foundation Honors CareDx with Corporate Citizenship Award for its Commitment to the Transplant Community

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the National Kidney Foundation honored CareDx with a corporate citizenship award during its 41st Annual Kidney Ball held on March 31, 2023, in Washington, D.C. Read the entire press release at CareDx.com.

Loading
Posted on

CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation

Loading

April 5, 2023

CareDx Exclusive Provider of dd-cfDNA Testing Services for Use in Miromatrix Clinical Trials

Companies at Forefront of Alternative Organ Supply Research to Address Organ Shortage

BRISBANE, Calif. & EDEN PRAIRIE, Minn.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. (“Miromatrix”) (Nasdaq: MIRO) – today announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.
Read the complete press release on CareDx.com.

Loading
Posted on

MIT Sloan School of Management researchers help redesign national lung transplant allocation system using data analytics

Loading

New system’s goal: Reduce overall deaths and increase access for patients waiting for lung transplants

CAMBRIDGE, Mass., March 28, 2023 /PRNewswire/ — United Network for Organ Sharing (UNOS) has rolled out a new organ allocation system designed to be more equitable and effective for patients in need of lung transplants. Read more from the MIT Sloan School of Management.

Loading
Posted on

CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association

Loading

MARCH, 23, 2023

CareDx to Host Symposium Featuring the Latest Developments in Pediatric Transplant Care

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its gold-level sponsorship and participation at the 12th Congress of the International Pediatric Transplant Association (IPTA) taking place March 25-28, 2023, in Austin, Texas. Read the complete press release on CareDx.com.

Loading
Posted on

The National Kidney Foundation Honors Johns Hopkins’ Dr. Tanjala Purnell for Transplantation Research

Loading

NEW YORK, March 13, 2023 /PRNewswire/ — Next month, Johns Hopkins University Associate Professor Tanjala S. Purnell, PhD, MPH, FASN will receive the National Kidney Foundation’s (NKF) Excellence in Transplantation Award at the 2023 NKF Spring Clinical Meetings in Austin, TX. This award recognizes the scientist or clinician scientist whose exceptional research has contributed novel insights to improved access to kidney transplantation. Read the press release from The National Kidney Foundation.

Loading